<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V</h1>
    <p class="timestamp">Published: 2016-05-12 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Rule</p>
    <p><strong>Agency:</strong> Justice Department, Drug Enforcement Administration</p>
    <p><strong>Document Number:</strong> 2016-11245</p>
    <p><strong>Publication Date:</strong> 2016-05-12</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2016/05/12/2016-11245/schedules-of-controlled-substances-placement-of-brivaracetam-into-schedule-v">https://www.federalregister.gov/documents/2016/05/12/2016-11245/schedules-of-controlled-substances-placement-of-brivaracetam-into-schedule-v</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2016-11245</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
